Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers

Table 3 Objective responses after two cycles of treatment in all evaluable patients (n = 39) and in the intention-to-treat population (n = 42).

Response	Number	% (evaluable pts)	% (ITT)
Total number of evaluable patients	39
Objective responses	19	49	45
Complete response	0	0	0
Partial response	19	49	45
Disease stabilization	11	28	26
Disease progression	9	23	21

ISSN: 1471-2407